ライフサイエンスコーパス: non-small-cell lung carcinoma

1 al microRNA (miR) expression is described in non-small cell lung carcinoma.

2 l tissue confirmed RS/DJ-1 overexpression in non-small cell lung carcinoma.

3 G1 cyclins D1 and E is reported in invasive non-small cell lung carcinoma.

4 with remarkable therapeutic efficacy against non-small cell lung carcinoma.

5 to induce DNA damage associated apoptosis in non-small cell lung carcinoma.

6 ction of treatment response in patients with non-small cell lung carcinoma.

7 e of angiogenesis) as a prognostic factor in non-small-cell lung carcinoma.

8 eatic carcinoma as well as in the H125 human non-small-cell lung carcinoma.

9 urred in patients with refractory breast and non-small-cell lung carcinoma.

10 d DUR index in 13 patients with grade 3 or 4 non-small-cell lung carcinoma.

11 ossibility of distinguishing small-cell from non-small-cell lung carcinoma.

12 ients with non-metastatic surgically treated non-small-cell lung carcinoma.

13 that has been investigated in patients with non-small-cell lung carcinoma.

14 MAGE-A4 was expressed in 48% of non-small cell lung carcinomas.

15 r p53 mutation or both (P = 0.01) in primary non-small cell lung carcinomas.

16 ll lung carcinomas and to a lesser extent in non-small cell lung carcinomas.

17 tor-positive gliomas, breast carcinomas, and non-small cell lung carcinomas.

18 und in the human bronchial epithelium and in non-small cell lung carcinomas.

19 ChR) stimulate growth of both small cell and non-small cell lung carcinomas.

20 ed with the development of a subset of human non-small cell-lung carcinomas.

21 whose expression is lost in >50% of primary non-small-cell lung carcinomas.

22 arization in a series of 500 primary stage I non-small-cell lung carcinomas.

23 eceptor (EGFR) are found in 15 to 30% of all non-small-cell lung carcinomas.

24 ), pancreatic duct carcinoma (4 of 4 cases), non-small cell lung carcinoma (5 of 5 cases), soft tissu

25 2 small cell lung cancer cell lines, 6 of 18 non-small cell lung carcinomas, 9 of 22 breast tumors, a

26 f 42) of breast carcinomas, 45% (5 of 11) of non-small cell lung carcinomas, 90% (9 of 10) of colon c

27 ted here demonstrate that treatment of human non-small cell lung carcinoma and bladder carcinoma cell

28 s, which are widely used in the treatment of non-small cell lung carcinoma and other late-stage tumor

29 p14ARF in 53 human cell lines and 86 primary non-small cell lung carcinomas and correlated this with

30 m A (RASSF1A) was observed in 40% of primary non-small cell lung carcinomas and in several tumor cell

31 of-the-art, mutant Kras-driven GEMMs--one of non-small-cell lung carcinoma and another of pancreatic

32 L/TRAIL sensitivity in pancreatic carcinoma, non-small-cell lung carcinoma and melanoma cell lines, a

33 MTDIA treatment inhibited A549 (human non-small cell lung carcinoma) and H358 (human bronchiol

34 Nineteen patients had non-small cell lung carcinoma, and 6 had small cell lung

35 l tissues but has been described in gliomas, non-small cell lung carcinomas, and breast carcinomas, h

36 p11.3, which is lost in approximately 60% of non-small cell lung carcinomas, and exhibits growth-supp

37 tomas, H-69 small cell lung carcinomas, H-23 non-small cell lung carcinomas, and MDA-MB-468 breast ca

38 static mesothelioma (n = 2), chemorefractory non-small-cell lung carcinoma, and bronchioloalveolar ca

39 rins, expressed on the cell surface of human non-small cell lung carcinomas, are used here as a targe

40 including childhood acute myeloid leukemia; non-small cell lung carcinoma; arthrogryposis multiplex

41 nstructed a genome-wide transcriptome map of non-small cell lung carcinomas based on gene-expression

42 mal growth factor receptor found on gliomas, non-small cell lung carcinomas, breast carcinomas, and o

43 ally effective in vivo against NCI-H23 human non-small-cell lung carcinomas, but this modality was su

44 evaluated against the COR-L23 parental human non small cell lung carcinoma cell line and the COR-L23/

45 show that siRNA-mediated TRPC1 depletion in non small cell lung carcinoma cell lines induced G(0)/G(

46 , mice were inoculated subcutaneously with a non-small cell lung carcinoma cell line and treated with

47 beta)-induced COX-2 expression in H358 human non-small cell lung carcinoma cell line by blocking CDK2

48 human liver AKN-1 cell line and in the human non-small cell lung carcinoma cell line, A-549, the abil

49 However, 24-h exposure of a non-small cell lung carcinoma cell line, NCI H157, to 10

50 3p12, and a 3p14.2 homozygous deletion in a non-small cell lung carcinoma cell line.

51 ung cancer in 13 small cell carcinoma and 17 non-small cell lung carcinoma cell lines and in 68 micro

52 G1 arrest and rapid apoptosis in three human non-small cell lung carcinoma cell lines with wild-type

53 When reintroduced into nonexpressing non-small cell lung carcinoma cell lines, this gene, nam

54 ted with the cytotoxicity of meayamycin B in non-small cell lung carcinoma cell lines.

55 ed levels of Bcl-2 and Bcl-XL proteins and a non-small-cell lung carcinoma cell line (NCI-H460).

56 play no direct role in the MDR phenotype in non-small cell lung carcinoma cells and that their cellu

57 sms by which EZH2 expression is regulated in non-small cell lung carcinoma cells by oncogenic KRAS.

58 erent administration schedules in A549 human non-small cell lung carcinoma cells in vitro.

59 ng overexpression of the mda-7 gene in human non-small cell lung carcinoma cells in vivo and its effe

60 In concordance, cultured SCLC but not non-small cell lung carcinoma cells showed no or extreme

61 arcinoma) and H358 (human bronchioloalveolar non-small cell lung carcinoma cells) xenograft tumor gro

62 in xenograft models based on human NCI-H460 non-small cell lung carcinoma cells.

63 dria and induced apoptosis in p53-null H1299 non-small cell lung carcinoma cells.

64 ced growth inhibition and apoptosis in human non-small cell lung carcinoma cells.

65 al interaction between MTOR and ponatinib in non-small cell lung carcinoma cells.

66 diaminobutanoic acid (9) against A549 human non-small-cell lung carcinoma cells in culture were 23 a

67 or some aggressive cancers, such as advanced non-small-cell lung carcinoma, combination immunotherapi

68 rker for the stratification of patients with non-small-cell lung carcinoma, combined with PD-L1 expre

69 In patients with non-small cell lung carcinoma, differential display show

70 Human non-small cell lung carcinoma expressed varying levels o

71 eletion at the FHIT locus in a series of 106 non-small cell lung carcinomas for which a full clinical

72 thylation profile of uscfDNA can distinguish non-small cell lung carcinoma from non-cancer samples.

73 tion, SIX1 and SIX2 protected RAS/P53-driven non-small-cell lung carcinomas from inflammatory cell de

74 gnant human tumors, including small-cell and non-small cell lung carcinomas, glioma, neuroblastoma, a

75 Here, using human non-small-cell lung carcinoma H1299 cells, we investigat

76 knocking down SSRP1 or Spt16 levels in human non-small cell lung carcinoma (H1299) cells.

77 Recent advances in therapy for non-small cell lung carcinoma have shown that a personal

78 on or suppression of pulmonary metastases of non-small cell lung carcinoma in both prophylactic and t

79 of cancer-related mortality worldwide, with non-small-cell lung carcinomas in smokers being the pred

80 A 60-year-old man with a non-small cell lung carcinoma (large cell type) presente

81 on in multiple tumor types, the RB-defective non-small cell lung carcinoma line H2009 and its RB-reco

82 sensitivities persisted in an additional 22 non-small cell lung carcinoma lines (ras mutations, n =

83 as detected in 40% of the tumors, whereas in non-small cell lung carcinomas, lymphomas, and head and

84 ressed in human hepatocellular carcinoma and non-small cell lung carcinoma, may facilitate cancer cel

85 of malignant cell lines including leukemia, non-small cell lung carcinoma, melanoma, and breast canc

86 Using a Kras-driven non-small cell lung carcinoma mouse model, we found that

87 have demonstrated that some other aggressive non-small-cell lung carcinomas (n-SCLC) do not have angi

88 (MCF-7), colorectal adenocarcinoma (HT-29), non-small cell lung carcinoma (NCI-H460), and glioblasto

89 ed as a first-line drug for cancers, such as non-small cell lung carcinoma (NSCLC) and bladder cancer

90 ) arm of chromosome 3 is a common finding in non-small cell lung carcinoma (NSCLC) and is postulated

91 ng both small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) and the second on

92 nts (34 male, 16 female, median age 73) with non-small cell lung carcinoma (NSCLC) and treated with I

93 the influence of overexpression of MYO1E in non-small cell lung carcinoma (NSCLC) and whether there

94 T cells from immunologically hot tumors like non-small cell lung carcinoma (NSCLC) are enriched in IC

95 w that VCP is significantly overexpressed in non-small cell lung carcinoma (NSCLC) as compared to nor

96 sed to identify chromosomal imbalances in 20 non-small cell lung carcinoma (NSCLC) biopsies and cell

97 Microarray data from cell lines of Non-Small Cell Lung Carcinoma (NSCLC) can be used to loo

98 in tobacco-related lung disease, stimulates non-small cell lung carcinoma (NSCLC) cell growth and su

99 onectin (Fn) stimulates the proliferation of non-small cell lung carcinoma (NSCLC) cell growth throug

100 expressed EGFR at levels comparable with the non-small cell lung carcinoma (NSCLC) cell line A549, as

101 ombesin receptor subtype 3 [BRS-3]) in human non-small cell lung carcinoma (NSCLC) cell lines and bro

102 Because the majority of human non-small cell lung carcinoma (NSCLC) cell lines are res

103 ntegrative genomic and proteomic analysis of non-small cell lung carcinoma (NSCLC) cell lines reveale

104 kinase inhibitor PF2341066 in MET-amplified non-small cell lung carcinoma (NSCLC) cell lines to iden

105 loss of DLC-1 protein expression identifies non-small cell lung carcinoma (NSCLC) cell lines whose g

106 This method was applied to human non-small cell lung carcinoma (NSCLC) cell lines, embedd

107 FN), a matrix glycoprotein, stimulates human non-small cell lung carcinoma (NSCLC) cell proliferation

108 e previously showed that nicotine stimulates non-small cell lung carcinoma (NSCLC) cell proliferation

109 atin and high-dose crizotinib induces ICD in non-small cell lung carcinoma (NSCLC) cells and effectiv

110 or cell proliferation and apoptosis in human non-small cell lung carcinoma (NSCLC) cells in vitro and

111 to be a potent inducer of apoptosis in human non-small cell lung carcinoma (NSCLC) cells through a nu

112 reductase, the silencing of which sensitized non-small cell lung carcinoma (NSCLC) cells to the cytot

113 S1 was also essential for PML degradation in non-small cell lung carcinoma (NSCLC) cells, and PML and

114 In studies performed in non-small cell lung carcinoma (NSCLC) cells, we found th

115 in various tumor cell lines including human non-small cell lung carcinoma (NSCLC) cells, which are r

116 nd discover the molecular targets of FHIT in non-small cell lung carcinoma (NSCLC) cells.

117 ated death worldwide, and among this cancer, non-small cell lung carcinoma (NSCLC) comprises the majo

118 tablished that PKCvarepsilon is required for non-small cell lung carcinoma (NSCLC) growth in vitro as

119 Here, we demonstrate that HH-dependent non-small cell lung carcinoma (NSCLC) growth is sensitiv

120 gnosis significance of TIL subpopulations in non-small cell lung carcinoma (NSCLC) have thus far not

121 ted from static and parametric PET images of non-small cell lung carcinoma (NSCLC) in order to provid

122 have demonstrated that NE differentiation in non-small cell lung carcinoma (NSCLC) is not uncommon.

123 Progression on therapy in non-small cell lung carcinoma (NSCLC) is often evaluated

124 Non-small cell lung carcinoma (NSCLC) is promoted by the

125 Non-small cell lung carcinoma (NSCLC) is the leading cau

126 lthough the Tumor-Node-Metastasis staging of non-small cell lung carcinoma (NSCLC) is the most effect

127 LKB1 tumor suppressor is a frequent event in non-small cell lung carcinoma (NSCLC) leading to the act

128 to EGF receptor (EGFR)-targeted therapies in non-small cell lung carcinoma (NSCLC) led to investigati

129 rsity of the macrophage compartment in human non-small cell lung carcinoma (NSCLC) lesions, here we p

130 he EGF receptor (EGFR) are effective in most non-small cell lung carcinoma (NSCLC) patients whose tum

131 othymidine ((18)F-FLT) PET in advanced-stage non-small cell lung carcinoma (NSCLC) patients with an a

132 y integrated platform to detect and quantify non-small cell lung carcinoma (NSCLC) rare genetic mutan

133 an be targeted to overcome the resistance of non-small cell lung carcinoma (NSCLC) to the AKT inhibit

134 iated with clinical benefit in patients with non-small cell lung carcinoma (NSCLC) treated with anti-

135 (GHRH) MZ-J-7-138 and JV-1-92 on H460 human non-small cell lung carcinoma (NSCLC) xenografted orthot

136 isms of action were investigated in NCI-H838 non-small cell lung carcinoma (NSCLC) xenografted s.c. i

137 promise to treat inoperable locally-advanced non-small cell lung carcinoma (NSCLC), a disease poorly

138 loss at chromosome 17q in the development of non-small cell lung carcinoma (NSCLC), and a number of k

139 umor-driving genes in patients with advanced non-small cell lung carcinoma (NSCLC), especially in tho

140 on characteristic of many cancers, including non-small cell lung carcinoma (NSCLC), head and neck squ

141 in pancreatic ductal adenocarinoma (PDAC) or non-small cell lung carcinoma (NSCLC), respectively, but

142 e overall survival in never smokers who have non-small cell lung carcinoma (NSCLC), we conducted a co

143 f deletion involving region 8p21-22 in human non-small cell lung carcinoma (NSCLC), we examined alter

144 As JNK is frequently activated in non-small cell lung carcinoma (NSCLC), we investigated t

145 his study was to characterize the effects of non-small cell lung carcinoma (NSCLC)-associated mutatio

146 The presence of a non-small cell lung carcinoma (NSCLC)-related gene or ge

147 A (HSP70) family, are often overexpressed in non-small cell lung carcinoma (NSCLC).

148 adioresistance in several cancers, including non-small cell lung carcinoma (NSCLC).

149 (TRAIL) is capable of inducing apoptosis in non-small cell lung carcinoma (NSCLC).

150 static disease to the brain in patients with non-small cell lung carcinoma (NSCLC).

151 cated in the growth and progression of human non-small cell lung carcinoma (NSCLC).

152 dazole ((18)F-FMISO) uptake in patients with non-small cell lung carcinoma (NSCLC).

153 erozygosity (LOH) on chromosome 3 at 3p21 in non-small cell lung carcinoma (NSCLC).

154 me 11q22-23 is observed at high frequency in non-small cell lung carcinoma (NSCLC).

155 in both small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC).

156 ldwide, and the majority of lung cancers are non-small cell lung carcinoma (NSCLC).

157 PET metrics and histopathologic response in non-small cell lung carcinoma (NSCLC).

158 ng anaplastic large-cell lymphoma (ALCL) and non-small cell lung carcinoma (NSCLC).

159 rmal tissue pairs from Chinese patients with non-small cell lung carcinoma (NSCLC).

160 alent in epithelial cancers, particularly in non-small cell lung carcinoma (NSCLC).

161 correlated with prognosis and progression of non-small cell lung carcinoma (NSCLC).

162 normal tissue samples from 17 patients with non-small cell lung carcinoma (NSCLC).

163 otherapy in patients with radically resected non-small cell lung carcinoma (NSCLC).

164 romising new therapeutic agents for treating non-small cell lung carcinoma (NSCLC).

165 BMP-2 is highly expressed in the majority of non-small cell lung carcinomas (NSCLC) but not in normal

166 vated in some lung tumors, the dependence of non-small cell lung carcinomas (NSCLC) for HH activity h

167 on protein is found in approximately 3-7% of non-small cell lung carcinomas (NSCLC).

168 on is increased in lung cancer, particularly non-small cell lung carcinomas (NSCLC).

169 Non-small-cell lung carcinoma (NSCLC) accounts for 85% o

170 Our current study using non-small-cell lung carcinoma (NSCLC) cell lines, animal

171 to its inhibitors and restores autophagy in non-small-cell lung carcinoma (NSCLC) cells with a TKI-s

172 roves the outcomes of patients with advanced non-small-cell lung carcinoma (NSCLC) harbouring epiderm

173 As therapy for locally advanced non-small-cell lung carcinoma (NSCLC) improves, brain me

174 Non-small-cell lung carcinoma (NSCLC) is among the deadl

175 ified the elevated level of EAPII protein in non-small-cell lung carcinoma (NSCLC) patients and NSCLC

176 identified that predict clinical response of non-small-cell lung carcinoma (NSCLC) patients to gefiti

177 ment of second- and third-line patients with non-small-cell lung carcinoma (NSCLC) with the epidermal

178 ceptor (EGFR) is frequently overexpressed in non-small-cell lung carcinoma (NSCLC), and EGFR inhibito

179 d and correlated with Akt hyperactivation in non-small-cell lung carcinoma (NSCLC), promotes tumour d

180 ions in small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC), the extent of suc

181 is more accurate than CT for the staging of non-small-cell lung carcinoma (NSCLC).

182 tin (CP) are the first-line chemotherapy for non-small-cell lung carcinoma (NSCLC).

183 d clinical outcome in patients with resected non-small-cell lung carcinoma (NSCLC; n = 248).

184 Immunohistochemical analysis of a cohort of non-small-cell lung carcinomas (NSCLC) indicated that 15

185 CLL); (4) normal versus colon tumor; and (5) Non-Small-Cell-Lung-Carcinoma (NSCLC) versus renal sampl

186 cember 2013, solid tumour samples (including non-small-cell lung carcinoma [NSCLC], colorectal carcin

187 the MAP kinase pathway activation common in non-small cell lung carcinomas (NSCLCs) and to extend th

188 ase (d-DT), have protumorigenic functions in non-small cell lung carcinomas (NSCLCs) but have AMPK-ac

189 eration and maintenance of Kras(G12V)-driven non-small cell lung carcinomas (NSCLCs).

190 tly observed in human cancers, but rarely in non-small cell lung carcinomas (NSCLCs).

191 Non-small-cell lung carcinomas (NSCLCs), which represent

192 ithelial adhesion and are often expressed in non-small-cell lung carcinomas (NSCLCs).

193 ng tumor cell lines, and 98 resected primary non-small-cell lung carcinomas (NSCLCs).

194 ous cell carcinoma, the two major classes of non-small-cell lung carcinomas (NSCLCs).

195 e antitumor activity of Taxol in a MDR human non-small cell lung carcinoma nude mouse xenograft model

196 Non-small-cell lung carcinomas of the superior sulcus, f

197 Non-small cell lung carcinoma patients are frequently tr

198 nated melanoma patients and three metastatic non-small cell lung carcinoma patients vaccinated with a

199 in anaplastic lymphoma kinase (ALK)-positive non-small-cell lung carcinoma patients, progression duri

200 rly results in patients with ROS1-rearranged non-small-cell lung carcinoma, recently emerging clinica

201 yzed, we observed that the majority (74%) of non-small cell lung carcinoma samples exhibited a signif

202 a subset of primary human cancers including non-small cell lung carcinoma, squamous cell skin carcin

203 Non-small cell lung carcinoma still maintains a poor 5-y

204 d that PPP2R2A was commonly downregulated in non-small cell lung carcinomas, suggesting that PPP2R2A

205 in 2014 to treat gastric adenocarcinomas and non-small cell lung carcinomas, targets vascular endothe

206 Strikingly, patients with non-small cell lung carcinoma that had received WGP trea

207 Finally, we found that non-small-cell lung carcinoma that presented a cytonucle

208 of combined-modality therapy for stage IIIA non-small cell lung carcinoma, the signs and symptoms of

209 Using non-small cell lung carcinoma to illustrate this approac

210 (34 men and 16 women; median age, 73 y) with non-small cell lung carcinoma treated with ICIs were pro

211 as in a panel of established small cell and non-small cell lung carcinoma tumor cell lines.

212 n (>50%) of DAL-1 was measured in 39 primary non-small cell lung carcinoma tumors as compared with pa

213 ome 18p11.3, which is lost in 38% of primary non-small cell lung carcinoma tumors.

214 nt response to chemotherapy in patients with non-small cell lung carcinoma using functional diffusion

215 A phase II trial of patients with advanced non-small-cell lung carcinoma using the 72-h infusion ev

216 in-embedded tumor samples from patients with non-small cell lung carcinoma, using a high-throughput a

217 Twenty-one of the twenty-four non-small-cell-lung carcinomas we analyzed express IWS1.

218 a, head and neck squamous cell carcinoma, or non-small cell lung carcinoma were eligible.

219 One hundred consecutive patients with non-small cell lung carcinoma were referred for CT evalu

220 novel therapeutic strategies for KRAS mutant non-small cell lung carcinoma with STK11 and/or KEAP1 co

221 endocrine small cell lung carcinomas, 4 of 4 non-small cell lung carcinomas with neuroendocrine pheno

222 In total, 27 patients with locally advanced non-small cell lung carcinoma (with or without solitary

223 zed Axl monoclonal antibodies that attenuate non-small cell lung carcinoma xenograft growth by downre

224 s-dependent human PANC-1 pancreatic and A549 non-small-cell lung carcinoma xenografts in nude mice, e

225 Systemic delivery to mice bearing human non-small-cell lung carcinoma xenografts results in a si